Daily Archives: April 7, 2020

Study suggests humans transported badgers from Britain to Ireland – Agriland

Posted: April 7, 2020 at 4:09 pm

A new study into badger genetics has shown those from thenorth-eastern and south-eastern counties of Ireland share genetics with badgers in Britain.

The study, just published in the journal Royal Society Open Science, was carried out by scientists from the Agri-food and Biosciences Institute (AFBI) in Northern Ireland and suggests people may have played a role in bringing badgers to Ireland.

The team worked with colleagues from the Department of Agriculture, Food and the Marine and the Waterford Institute of Technology in the Republic of Ireland, to assemble a larger, island-wide set of 545 badger samples.

Badgers from the island of Ireland have previously been the subject of several genetic studies which compared their heritage to those of badgers from other European countries.

However, previous studies were based on small numbers of animals from only a few Irish locations. The extent of the influence of British animals on the Irish population, and the timing and mechanism of any potential import events remained unclear.

Ireland has fewer mammal species than Britain and continental European neighbours because of its geological history.

Ireland became an island around 15,000 years ago, at a time when glaciers were retreating from northern Europe, permitting recolonisation by animals that had retreated to more temperate, southern climes at the height of the last ice age.

Consequently, natural colonisation routes for animals into Ireland were barred for all but those species that could fly.

As a result, how Ireland came to acquire the fauna it possesses in modern times, is one of the great puzzles of modern biology.

These revealed that Irish badgers had a mixed genetic profile sharing similarities with animals from Britain and Scandinavia and suggesting they may have been moved from those territories into Ireland by human agency.

The new study by AFBI looked into a much bigger sample size than typical before. Aside from the 545 local samples, collaborators at the Universities of Glasgow, Oxford and Exeter and the Animal and Plant Health Agency (APHA) provided a further 91 samples from badgers from Britain.

The population genetic analyses revealed that badgers with British genetic heritage are localised in north-eastern and south-eastern counties in Ireland and that human-aided import of badgers from Great Britain, around 700 years ago, is the most probable explanation.

Although anecdotal, it is notable that humans from these same regions in Ireland also exhibit genetic and genealogical links to Great Britain, an observation thought to result from the Plantations of Ireland that occurred in the 13th and 16th centuries.

The findings improve scientists knowledge of how Irelands modern mammal populations have been formed as well as the population structure of badgers in Ireland.

RELATED STORIES

Read the rest here:
Study suggests humans transported badgers from Britain to Ireland - Agriland

Posted in Human Genetics | Comments Off on Study suggests humans transported badgers from Britain to Ireland – Agriland

Indians do not have genetic protection against coronavirus, published research incorrectly interpreted – Alt News

Posted: at 4:08 pm

An opinion piece published on Livemint by Sandipan Deb claimed that COVID-19 will not affect Indians as they have the genetics for a sturdier immune system.

When questioned on Twitter, the author, also a founder of Swarajya Magazine, cited a Nature Asia article titled, More immunity in Indian genes, as his source.

The Nature Asia article (2008), based on the research study by Du and colleagues (2008), published in the journal Genes & Immunity was conducted by a team of scientists from the University of California in Los Angeles (UCLA), USA, All India Institute of Medical Sciences, India (AIIMS), and National Marrow Donor Program (NMDP), USA.

More immunity in Indian genes The title of Nature Asia magazine article.

Our bodies have one of the toughest immune systems in the world. We have grown up surrounded by so much filth and pollution that our natural resilience is much stronger than people in the developed world. Sandipan Deb in Livemint.

False.

1. The Livemint article is based on a superficial understanding of the title of the Nature Asia, not its text.

The Nature Asia article is titled More immunity genes in Indians. However, the article itself does not make any such claims that, on the basis of the research study quoted, that Indians will be protected from the coronavirus pandemic or other infections due to their biologically inherited resilience. It simply states that Indians may have more genes linked with immunity as per the data. Also, one of the authors of the article and the research study Rajalingam Raja wrote, Whether having more activating KIR genes is an advantage or disadvantage for Indians remains to be elucidated.

This means that the genes tested through this study are not a piece of conclusive evidence that the contested tougher immunity will be an advantage for Indians in any way.

2. The Nature Asia article is based on a research study based on a single gene polymorphism in various ethnicities.

The Nature Asia article is based on a research study which relies upon a single gene KIR2DL5 polymorphism in many ethnicities including Indian, East Asian, white (Caucasian) and black (African Americans), suggesting that the gene is not unique to Indians only. Also, no evidence suggests that the presence of gene translates to gene expression or phenotypic change (e.g. higher immunity) in this case.

Nature Asia article based its claim on a gene polymorphism study by Du and colleagues (2008). Genetic polymorphism is the occurrence of multiple forms of a single gene which is expressed in the same population as a trait or a phenotype (Bull, 2004). It is similar, but not the same, as varying levels of pigmentation in eyes, hair or skin colour.

The study quoted showed the nature of polymorphism of one gene KIR2DL5 in four ethnic groups: Caucasians (European race, mostly white), Asian-Indians (South Asians), African-Americans and Asians (East Asians, i.e. Korean, Vietnamese, Japanese and Filipino).

KIR2DL5 (or CD158f) is the last identified KIR gene (the inhibitory receptor expressed on the surface of immune cells), with KIR2DL4, it makes up a structurally divergent lineage conserved in different primate species such as humans. The percentage frequency of this KIR2DL5 gene in Indians is used as an indicator of higher immunity.

The graph from the research study illustrates that the percentage frequency of KIR2DL5 (A and B, polymorphic forms of KIR2DL5 gene) is higher in Asian Indians than the other ethnic populations studied. However, the graph below from the same study suggests that the Individuals carrying the KIR2DL5 gene vary substantially among populations ranging in frequency from 35-85%. Thus, as per the authors conclusions, higher immunity can be found in every ethnicity ranging from 35-85% population, not just in Indians.

Hence, with such large variability in genes in each population, it is impossible to deduce that the researchers certainly found the KIR2DL5 gene more frequently in Indian ethnicities, as compared to other ethnicities.

Also, the research paper doesnt claim that this higher frequency in Asian-Indians population is linked to a better immune system or more natural killer cells in the body. In fact, there are no conclusions drawn on any ethnic group being genetically superior or inferior regarding immunity.

3. Is the occurrence of genes (KIR2DL5 gene) linked with immunity synonymous with its traits (tougher immunity)?

The occurrence of more genes in a population isnt always synonymous with better traits. This is mainly because a greater amount of genes doesnt always translate to a protein abundance, which consequently becomes a trait. That is, the presence of genes doesnt always lead to the presence of characteristic traits related to the expression of the gene.

Sometimes, polymorphic changes in natural killer cells can also be associated with a susceptibility towards certain diseases (Orange, 2002). Thus, more correlative studies should be conducted where a higher frequency of KIR2DL5 gene results in an increased immunity regardless of ethnicity.

4. Smaller sample size

The beneficial effects of higher frequency of a polymorphic gene in a population can only be established after detailed protein, genomics and evolutionary studies with large sample size. But in this study, only 96 Indian genomes were studied as opposed to 250 Caucasians. Hence, these higher percent frequencies of polymorphs KIR2DL5 gene could also be an artefact resulting from a smaller sample size.

Only 96 non-randomised samples for the Asian-Indian group were sourced from New Delhi, which is a minuscule representation for the Indian population. These sample sizes were further reduced after identification of KIR2DL5 positive individuals.

Also, the Nature Asia article further claims that Indians gained the activating KIR (killer cell immunoglobulin-like receptors) genes because of natural selection to survive the environmental challenges during their pre-historic coastal migrations from Africa. This conclusion is not based on any evidence.

Dr Mehra, former Dean of AIIMS, in his opinion piece in The Print mentions the results from the same study that includes SK Sharma of AIIMS, to make his claims about the genetic advantage of Indians over Caucasians with respect to immunity against the coronavirus. Additionally, Dr Mehra also included other factors that may give Indians advantage broad-based immunity due to overexposure to other pathogens, and epigenetic factors such as environment and consumption of Indian spices in cuisine. However, since the novelty of the virus and the increasing pathogenesis of SARS-CoV-2 in India, these claims remain without any research or evidence in Science.

The Nature Asia article published a misleading title on the basis of a genetics study which was termed inconclusive by the authors in their own research study. This title formed the basis of the Livemint article by Mr Deb.

The Nature Asia authors generalised their misleading article about Natural Killer cells (NK) to immunity genes. Natural killer cells are a small component of what makes up human immunity, not the expansive immune system.

Later, in the Livemint article, the Nature Asia article was used to claim a blanket superiority of the immune system of Indians. Mr Deb stated that Indians immune system is more robust than the people in the developed world to tackle the coronavirus pandemic.

Such dangerous opinion pieces with no understanding of the genetics of immunity have the potential to drive people to be careless with the protocols issued by the government on social distancing and other precautions or to encourage reckless behaviour during a critical situation.

Du, Z., Sharma, S. K., Spellman, S., Reed, E. F., & Rajalingam, R. (2008). KIR2DL5 alleles mark certain combination of activating KIR genes. Genes & Immunity, 9(5), 470-480.

Bull, L. (2004). Genetics, Mutations, and Polymorphisms. Molecular Pathogenesis of Cholestasis, 77-95.

Estefana, E., Flores, R., Gmez-Lozano, N., Aguilar, H., Lpez-Botet, M., & Vilches, C. (2007). Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. The Journal of Immunology, 178(7), 4402-4410.

Orange, J. S. (2002). Human natural killer cell deficiencies and susceptibility to infection. Microbes and infection, 4(15), 1545-1558.

Donate Now

Related

Read more:
Indians do not have genetic protection against coronavirus, published research incorrectly interpreted - Alt News

Posted in Human Genetics | Comments Off on Indians do not have genetic protection against coronavirus, published research incorrectly interpreted – Alt News

Caviarlieri: The World’s Only Caviar Food Supplement with the Latest Innovation in Swiss Cellular Therapy Technology – Yahoo Finance

Posted: at 4:07 pm

SINGAPORE, April 7, 2020 /PRNewswire/ -- Encapsulating the potent bioactive nutrients of Caviar into a supplement has been a dream and a formidable challenge for the Anti-Aging Medical World for several decades. Caviarlieri Limited, through its global panel of Anti-Aging medical experts has been able to create after 20 years of intensive research, this Age-Defying Caviar Supplement, Caviarlieri.

Unprecedented in its potency, the rare Sturgeon black caviar is rich in essential fatty acids and contains unique active pharmaceutical ingredients (API). Manufactured using its proprietary Swiss Cold DNA Extraction technology "Cellularix", Caviarlieri contains the potent Caviar Cellular DNA Extracts and effective bioactive Marine peptides resulting in a supplement, unparalleled in energy, vitality and beauty.

Unlike other food supplements, Caviarlieri provides essential nutrition directly at the cellular level, thereby enabling its optimal absorption into the cells because of its bioavailability. These caviar proteins and peptides are able to easily enter into the cells, triggering enhanced cell activity and stimulation, resulting in immense energy, ageless performance, enhanced vitality and timeless beauty.

Backed by extensive research, Caviarlieri has scientific studies which are published in peer-reviewed journals. It also has a empirical double blind placebo controlled studies on its key ingredients. Further research is still ongoing in the US, Switzerland and Europe on genetic expression in key biomarkers which defy the aging process.

Caviarlieri - The Only Swiss Caviar Cellular Therapy Supplement in the World

Researched, developed and made in Switzerland, Caviarlieri works on multiple levels of the human body and its benefits are diverse, extensive and its effects vary among individuals. Almost all of our customers are unanimous when they report improved energy levels, better sleep quality, enhanced skin complexion, significant reduction in joint pain, mood elevation, increased sexual desire and libido.

"Cell Regeneration is activated in Caviarlieri," said Dr. med. Brigitte Bollinger, Specialist FMH for Dermatology, Medical Center Bad Ragaz, Switzerland. "It can produce outstanding results in areas like strengthening the immune system, reducing chronic inflammation significantly, alleviating metabolic syndrome, improving physical stamina, providing faster recuperation after exercise, improving mental focus, enhancing sexual performance, satisfaction and many more."

Caviarlieri is clinically proven to accelerate cellular renewal and repair versus damaged or dysfunctional immune cells and potentially help to strengthen our immune system against viruses and diseases. Its powerful antioxidant and anti-inflammatory properties can prevent cell damage, enhance our immune responses and effectively combat inflammation.

Caviarlieri is available in most exclusive luxury Spas and Medical Centres and pharmacies throughout Switzerland.

Caviarlieri Limited

Caviarlieri Limited is committed to the development and creation of Anti-Aging Swiss Cellular Therapy products through significant investment in research and clinical studies. Caviarlieri is manufactured by Swiss Caps Inc (a USA-FDA approved and inspected facility) with cGMP certification. Certified and approved by the Swiss Public Health Authority, Caviarlieri complies with the BRC Global Standard for Food Safety. Caviarlieri is also certified by the German Sport University Cologne as a supplement free of steroids and stimulants.

Related Links: https://swisscaviarlieri.com/

Media Contact:

Mr. Shane WMarketing DirectorCaviarlieri Limited+41-445510014marketing@swisscaviarlieri.com

Photo - https://photos.prnasia.com/prnh/20200319/2755986-1

SOURCE Caviarlieri Limited

Read more here:

Caviarlieri: The World's Only Caviar Food Supplement with the Latest Innovation in Swiss Cellular Therapy Technology - Yahoo Finance

Posted in Food Supplements | Comments Off on Caviarlieri: The World’s Only Caviar Food Supplement with the Latest Innovation in Swiss Cellular Therapy Technology – Yahoo Finance

Axonics Submits PMA Supplement to U.S. Food & Drug Administration to Expand Full-Body MRI Labeling for 3T Scans – Business Wire

Posted: at 4:07 pm

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the submission of a premarket approval (PMA) supplement to the U.S. Food & Drug Administration (FDA) for the purpose of gaining full-body magnetic resonance imaging (MRI) conditional labeling for 3.0T MRI scans.

In September 2019, the FDA approved the Axonics r-SNM System with full-body conditional labeling for 1.5T MR scanners. Axonics has since performed all the required tests to support a PMA supplement for full-body conditional labeling on 3.0T MR scanners for the implantable components of its r-SNM System. The FDA review timeline for labeling expansion PMA supplements is 180 days.

Raymond W. Cohen, Axonics CEO commented, The Axonics r-SNM System is already approved for 1.5T and 3.0T full-body MRI scans in Europe. While only approximately 15% of MRI scanners operating in the U.S. are 3.0T, we believe it was a worthwhile investment to conduct the testing and analyses required for this filing and we are confident our PMA supplement will meet all criteria for FDA approval. This submission further demonstrates Axonics commitment to continuous innovation for the benefit of patients, clinicians and the healthcare system.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. SNM therapy has been employed to reduce symptoms and restore pelvic floor function for the past two decades. Reimbursement coverage is well established in the U.S. and Europe. The Axonics System is the first long-lived rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit the Companys website at http://www.axonics.com.

Forward-Looking Statements

Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as planned, expects, believes, anticipates, designed, and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at http://www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

See more here:

Axonics Submits PMA Supplement to U.S. Food & Drug Administration to Expand Full-Body MRI Labeling for 3T Scans - Business Wire

Posted in Food Supplements | Comments Off on Axonics Submits PMA Supplement to U.S. Food & Drug Administration to Expand Full-Body MRI Labeling for 3T Scans – Business Wire

Axonics submits PMA supplement to US Food & Drug administration to expand full-body MR labeling for 3T scans – DOTmed HealthCare Business News

Posted: at 4:07 pm

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the submission of a premarket approval (PMA) supplement to the U.S. Food & Drug Administration (FDA) for the purpose of gaining full-body magnetic resonance imaging (MRI) conditional labeling for 3.0T MRI scans.

In September 2019, the FDA approved the Axonics r-SNM System with full-body conditional labeling for 1.5T MR scanners. Axonics has since performed all the required tests to support a PMA supplement for full-body conditional labeling on 3.0T MR scanners for the implantable components of its r-SNM System. The FDA review timeline for labeling expansion PMA supplements is 180 days.

Raymond W. Cohen, Axonics CEO commented, The Axonics r-SNM System is already approved for 1.5T and 3.0T full-body MRI scans in Europe. While only approximately 15% of MRI scanners operating in the U.S. are 3.0T, we believe it was a worthwhile investment to conduct the testing and analyses required for this filing and we are confident our PMA supplement will meet all criteria for FDA approval. This submission further demonstrates Axonics commitment to continuous innovation for the benefit of patients, clinicians and the healthcare system.

Ad StatisticsTimes Displayed: 1013897Times Visited: 8831

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

Source: Axonics Modulation Technologies, Inc.

See the original post:

Axonics submits PMA supplement to US Food & Drug administration to expand full-body MR labeling for 3T scans - DOTmed HealthCare Business News

Posted in Food Supplements | Comments Off on Axonics submits PMA supplement to US Food & Drug administration to expand full-body MR labeling for 3T scans – DOTmed HealthCare Business News

Functional Food and Beverages Market to Rise at 8.49% CAGR till 2026; Increasing Health Awareness in Urban Areas to Fuel Market Expansion: Fortune…

Posted: at 4:07 pm

Pune, April 07, 2020 (GLOBE NEWSWIRE) -- The global functional foods and beverages market size is projected to reach USD 412.22 million by 2026, exhibiting a CAGR of 8.49% during the forecast period. Increasing malnutrition worldwide will be the primary growth driver for this market in the near future, shares Fortune Business Insights in its new report, titled Functional Foods and Beverages Market Size, Share & Industry Analysis, By Type (Cereals & Grains, Fats & Oils, Dairy Products, Bakery Products, and Other Functional/Fortified Foods) Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, Online Retail, and Others), and Regional Forecasts, 2019 2026.

According to the World Health Organization (WHO), close to 462 million people are underweight and 52 million children under the age of 5 are suffering from wasting. Moreover, roughly 45% of deaths among children below 5 years of age occur due to under-nutrition. As a result, governments have spurred into action in both developed and developing countries. For instance, in 2019, the UK government made it mandatory to fortify flour with folic acid to prevent occurrence of congenital disabilities in children. Similarly, in July 2019, the Indian government announced distribution of rice fortified with folic acid, Vitamin B12, and iron through the Public Distribution System (PDS). The market for functional foods and beverages, thus, stands to gain from these developments.

The functional food and beverages market report states that the value of this market stood at USD 216.25 million in 2018. Other than this, the report contains the following:

Request a Sample Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/functional-foods-market-102269

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Click here to get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/functional-foods-market-102269

Competitive Landscape

Development of Exciting Products to Stimulate Intense Competition

One of the leading functional food and beverages market trends is the increasing focus of key players on the developing and launching new and exciting products in the market. Not only do these frequent launches help companies solidify their position in the market, but they also periodically realign the overall dynamics of market competition.

List of Key Companies Covered in the Functional Foods and Beverages Market Research Report are:

The Coca-Cola Company

Celsius Holdings, Inc.

PepsiCo, Inc.

Glanbia plc

Nestle S.A.

Arla Foods amba

Hearthside Food Solutions LLC

Tyson Foods, Inc.

General Mills, Inc.

Danone S.A.

Market Driver

High Nutritional Value of Functional Foods to Spike Uptake

The popularity of fortified food and beverages has been steadily climbing in recent years, mainly due to the hectic and unhealthy lifestyles people are leading in urban areas. As a result, there is a growing demand for nutrition-rich food and beverage items fueled by rising health and wellness concerns. Functional foods have emerged as an attractive option for many consumers, given their wide-ranging and long-term benefits.

For example, functional foods and beverages fortified with omega-3 fatty acids can boost brain function, secure heart health, and reduce inflammation. The benefits of functional foods are not limited to just chronic and lifestyle-based disorders; they have proven efficacy in tackling the effects of under-nourishment too. For example, the National Institutes of Health reported that the introduction of wheat flour fortified with iron in Jordan led to 50% reduction in the incidence of iron deficiency anemia among children.

Regional Analysis

Evolving Lifestyles in Asia-Pacific to Aid the Region Register Impressive CAGR

Asia-Pacific is slated to dominate the functional food and beverages market share and grow at a CAGR of 9.20% during the forecast period. The central reason for this rise is the rapidly changing lifestyles of people that are increasing the prevalence of chronic conditions in the region. An example of this is the increasing consumption of fast or junk food. Thus, there is a surging demand for nutritional foods as people are getting more health conscious, especially in India. In addition to foodstuffs, there is also a high demand for functional hydration, particularly in tropical countries where water loss from the body is high. After Asia-Pacific, North America is expected to be the second-largest region for this market, anticipated to register a CAGR of 7.06% in the forthcoming years.

Quick Buy - Functional Foods and Beverages Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102269

Detailed Table of Content:

TOC Continued!

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/functional-foods-market-102269

Industry Developments:

Have a Look at Related Research Insights:

Functional Beverage Market Size, Share & Industry Analysis, By Type (Fortified Juice, Energy Drink, Sports Drink, Dairy-based Beverage, Enhanced Water, Others), By Distribution Channel (Supermarket/Hypermarket, Departmental Stores, Health Stores, Online Stores, Others), and Regional Forecast 2019-2026

Functional Flour Market Size, Share and Global Trend by Source (Rice, Tapioca, Sunflower, Linseed, Lentils, Wheat), Type (Pre-cooked Flour, Fortified Flour, Specialty Flour), Product Type (Additive-based Flour, Conventional Flour, Genetically Modified Flour), Application (Baked Goods, Pasta, Noodles, Soups, Gravies, Sauces), Distribution Channel (B2B, B2C) and Geography Forecast till 2025

Functional Food Ingredients Market Size, Share and Global Trend By Type (Vitamins, Minerals, Prebiotics, Probiotics, Hydrocolloids, Essential Oils, Omega Fatty Acids, Carotenoids), Purpose (Weight Management, Digestive Health, Cardio Health), Application (Beverages, Bakery, Dairy, Snacks) and Geography Forecast till 2026

Functional Mushrooms Market Size, Share & Industry Analysis, By Type (Cordyceps, Reishi, Turkey Tail, Shiitake, Lions Mane, Chaga), By Application (Functional Food & Beverage, Dietary Supplements, Personal Care, Pharmaceuticals) and Regional Forecast, 2019-2026

Functional Water Market Size, Share and Industry Analysis By Ingredient (Micronutrients, Botanical Extracts, Other Functional Ingredients), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, Online Retail, Others), and Regional Forecast 2018-2025

Functional Proteins Market Size, Share & Industry Analysis, By Type (Whey Protein, Casein Protein, Soy Protein, Hemp Protein, Pea Protein, Other Functional Proteins), By Form (Concentrates, Isolates, Hydrolysates), By Application (Dietary Supplements, Functional Foods, Functional Beverages, Animal Nutrition)and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:Fortune Business Insights Pvt. Ltd.308, Supreme Headquarters,Survey No. 36, Baner,Pune-Bangalore Highway,Pune - 411045, Maharashtra, India.Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.com Fortune Business InsightsLinkedIn | Twitter | Blogs

Read Press Release: https://www.fortunebusinessinsights.com/press-release/functional-foods-and-beverages-market-9718

Excerpt from:

Functional Food and Beverages Market to Rise at 8.49% CAGR till 2026; Increasing Health Awareness in Urban Areas to Fuel Market Expansion: Fortune...

Posted in Food Supplements | Comments Off on Functional Food and Beverages Market to Rise at 8.49% CAGR till 2026; Increasing Health Awareness in Urban Areas to Fuel Market Expansion: Fortune…

Nutrition/Dietary Supplements Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 – Science In Me

Posted: at 4:06 pm

New Jersey, United States: Market Research Intellect has added a new research report titled, Nutrition/Dietary Supplements Market Professional Survey Report 2020 to its vast collection of research reports. The Nutrition/Dietary Supplements market is expected to grow positively for the next five years 2020-2026.

The Nutrition/Dietary Supplements market report studies past factors that helped the market to grow as well as, the ones hampering the market potential. This report also presents facts on historical data from 2011 to 2019 and forecasts until 2026, which makes it a valuable source of information for all the individuals and industries around the world. This report gives relevant market information in readily accessible documents with clearly presented graphs and statistics. This report also includes views of various industry executives, analysts, consultants, and marketing, sales, and product managers.

Key Players Mentioned in the Nutrition/Dietary Supplements Market Research Report:

Market Segment as follows:

The global Nutrition/Dietary Supplements Market report highly focuses on key industry players to identify the potential growth opportunities, along with the increased marketing activities is projected to accelerate market growth throughout the forecast period. Additionally, the market is expected to grow immensely throughout the forecast period owing to some primary factors fuelling the growth of this global market. Finally, the report provides detailed profile and data information analysis of leading Nutrition/Dietary Supplements company.

Nutrition/Dietary Supplements Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Nutrition/Dietary Supplements market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Nutrition/Dietary Supplements .

The Nutrition/Dietary Supplements Market research presents a study by combining primary as well as secondary research. The report gives insights on the key factors concerned with generating and limiting Nutrition/Dietary Supplements market growth. Additionally, the report also studies competitive developments, such as mergers and acquisitions, new partnerships, new contracts, and new product developments in the global Nutrition/Dietary Supplements market. The past trends and future prospects included in this report makes it highly comprehensible for the analysis of the market. Moreover, The latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Nutrition/Dietary Supplements market have also been included in the study.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.marketresearchintellect.com/ask-for-discount/?rid=211722&utm_source=SI&utm_medium=888

Table of Content

1 Introduction of Nutrition/Dietary Supplements Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nutrition/Dietary Supplements Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nutrition/Dietary Supplements Market, By Deployment Model5.1 Overview

6 Nutrition/Dietary Supplements Market, By Solution6.1 Overview

7 Nutrition/Dietary Supplements Market, By Vertical7.1 Overview

8 Nutrition/Dietary Supplements Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nutrition/Dietary Supplements Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.marketresearchintellect.com/product/global-nutrition-dietary-supplements-market-size-and-forcast/?utm_source=SI&utm_medium=888

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Nutrition/Dietary Supplements Market Size, Nutrition/Dietary Supplements Market Growth, Nutrition/Dietary Supplements Market Forecast, Nutrition/Dietary Supplements Market Analysis, Nutrition/Dietary Supplements Market Trends, Nutrition/Dietary Supplements Market

See the original post:

Nutrition/Dietary Supplements Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 - Science In Me

Posted in Food Supplements | Comments Off on Nutrition/Dietary Supplements Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 – Science In Me

OptiBiotix agrees contract manufacturing deal with French supplements and nutrition group – Proactive Investors UK

Posted: at 4:06 pm

The move follows on from a tie-up last week with Denmarks Fipros, which will produce food additive SlimBiome under license for distribution across the EU.

() has signed a contract manufacturing agreement with French food supplements and nutrition group, Laboratoire PYC.

The new partner has the exclusive rights to manufacture meal replacement shakes for the UK firms GoFigure weight management range.

OptiBiotix said the deal helps de-risk its supply chain. It follows on from a tie-up last week with Denmarks Fipros, which will produce food additive SlimBiome under license for distribution across the EU.

The [latest] agreement helps us lower the cost of trade in case of a hard Brexit, supports our existing and future European distributors, and builds contingency into the supply chain: a key requirement from large retail partners who do not want to be single-sourced, Dr Fred Narbel, managing director of OptiBiotix's prebiotics division said in a statement.

In addition, Laboratoire PYC has a large portfolio of product formulations which can be formulated with SlimBiome enabling us to increase the number of applications, extend our product range, and shorten the development of new GoFigure, SnackSmart and SnackWell products without incurring significant development costs."

The company has developed or is developing products and treatments for obesity, high cholesterol, diabetes and skincare that target the human microbiome, a bacterial ecosystem found in the gut and on the skin.

Read more:

OptiBiotix agrees contract manufacturing deal with French supplements and nutrition group - Proactive Investors UK

Posted in Food Supplements | Comments Off on OptiBiotix agrees contract manufacturing deal with French supplements and nutrition group – Proactive Investors UK

We Could Be Taking Psychedelics to Help Treat Mental Illness in Just Five Years – Newsweek

Posted: at 4:04 pm

Psychedelic drugs could be commonly used to treat mental health patients in as little as half a decade, according to a leading expert in the field.

David Nutt, professor and neuropharmacologist at Imperial College London and former U.K. government drug adviser, told Newsweek he believes we are "less than five years" away from such drugs being given to patients.

Nutt made the forecast after co-authoring a commentary in the journal Cell, which explores the resurgence of research investigating the potential benefits of using drugs such as LSD and magic mushrooms in controlled medical settings to treat mental disorders like depression, anxiety and PTSD.

During the 1950s and 1960s, LSD was researched widely and considered a potential breakthrough drug by psychiatrists, according to the team, but work ground to a halt after such substances were taken recreationally and subsequently banned.

In the article, Nutt and colleagues argue that the war on drugs, which ended such research, was "one of the worst examples of censorship of human research in the history of science."

"In the past decade, research on these compounds has been re-established by a few groups around the world, culminating in new centers for psychedelic research at Imperial College London and Johns Hopkins University," they said.

For instance, after "battling" with regulators to use the schedule 1 drug psilocybin, the active ingredient in magic mushrooms, researchers found "remarkable" effects on patients who were given it alongside psychological support. Two experiences with the drug appeared to ease symptoms of depression in some people for weeks, and even years "positioning it as one of the most powerful therapeutics for treatment-resistant depression," the team wrote.

Nutt and colleagues will soon finish a trial comparing psilocybin with the antidepressant drug escitalopram on patients with depression.

The writers said psychedelics may have a profound effect on participants in such trials, as patients suffering from conditions like anxiety and depression often dwell too much on negative thoughts, such as their own failings, and the combination of these drugs and therapy sessions seem to break these cycles.

"Standard antidepressants protect against the stressors that lead to and perpetuate depression, but don't directly access and remedy underlying biopsychosocial causes," the team wrote.

"In contrast, psychedelic therapy harnesses a therapeutic window opened up by the brain via the effects of the drugs to facilitate insight and emotional release and, with psychotherapeutic support, a subsequent healthy revision of outlook and life-style."

However, more work is needed, they said, to explain the mechanism behind the effects of these drugs.

The writers also cast doubt on microdosing, where drugs are taken at small enough doses not to change a person's state in any conceivable way but which some claim can balance a person's mood. A study last year concluded there is no evidence to show the practice works. Nutt and colleagues questioned how, for instance, microdosing psilocybin three times a week could elicit the same effect as a "macrodose" used in trials where participants have experiences that are "variously called breakthrough, peak, or mystical."

Nutt and his co-authors also argued that regulators should consider rescheduling psychedelics drugs, particularly psilocybin, in order to make it easier for them to be studied by researchers.

"The resurrection of research into the neuroscience and therapeutic application of psychedelics represents one of the most important initiatives in psychiatry and brain science in recent decades," they wrote.

The team concluded: "What is now needed is a combined, multi-level, multidisciplinary program of research into the mechanisms underpinning" recent finding on psychedelics."

Ravi Das of the UCL Clinical Psychopharmacology Unit, who did not work on the commentary, told Newsweek: "I am in complete agreement with Professor Nutt that we need more robust research into whether these drugs are effective and particularly into how they produce beneficial changes."

Das said he agreed that it could be beneficial to reschedule certain psychedelics so they are easier to research and gather "proper empirical data" on.

"The way drugs are currently classified legally has little relation to their underlying pharmacology, toxicity, or potential for harm or benefit," said Das. "The psychedelic drugs Nutt reviews are far less toxic than alcohol and tobacco, for example, with much greater potential for benefit."

Asked how many years he predicts will pass before psychedelics are commonly used to treat patients, Das said: "Owing to the stagnation in psychiatry that Nutt and colleagues note in their review, research scientists and psychiatrists tend to get excited about new 'step-change' developments in treatment approaches."

Das said there was a tendency, particularly in private clinics in the U.S. to offer treatments too prematurely, before mechanisms are properly understood.

Read more

"I have no doubt that we will see private clinics offering such treatments in the next few years, albeit without a solid empirical grounding. Nutt and colleagues highlight the need for mechanistic research into these drugs and I think this is critical to ensuring they are used most effectively and safely in disorders where they are likely to have most benefit," said Das.

The take-home message for the general public is clear, according to Das and Nutt.

Nutt told Newsweek it is unsafe for the general public to experiment with psychedelic drugs at home, as the powerful therapies require trained medical supervision. Drugs like LSD, for instance, can trigger mental health problems, according to health officials.

Das said many people use psychedelics recreationally and do not experience the lasting, or "life-changing" insights some study participants report.

"There is therefore no guarantee that experimenting at home will have effects remotely like those seen in carefully controlled studies," he said. "Given that the leading researchers in the field still don't really understand how psychedelics work to improve mental health, those choosing to experiment at home would be truly 'flying blind'. As with all potential psychiatric treatments, potential psychedelic therapies should be overseen by a qualified healthcare professional."

Das concluded: "I do think there is real promise in psychedelic therapies and agree with Nutt et al's recommendations on almost all fronts.

"I would like to stress, however, that we're really still at the very early stages of this research and understanding how these drugs work. Whether they truly represent the 'revolution' in psychiatry some tout them to be still needs to be shown by research."

See the original post here:

We Could Be Taking Psychedelics to Help Treat Mental Illness in Just Five Years - Newsweek

Posted in Psychedelics | Comments Off on We Could Be Taking Psychedelics to Help Treat Mental Illness in Just Five Years – Newsweek

Magic mushrooms to treat depression? COMPASS Pathways pushes forward with U.S. patent for psilocybin therapy – Straight.com

Posted: at 4:04 pm

Back in early 2018, the Straight published a cover story on the growing field of research into psychedelic plants and chemicals.

This wasn't the paper's first foray into this field, of course.

In its earliest days as a poineering alt-weekly, the Straightspilled pleny of inkon this topic.

Most notably, artist Rand Holmes ran the legendary Harold Hedd comic strip in the paper in the early 1970s, featuring a beloved, long-haired, drug-loving hippie.

More recently in 2007, there was a feature in the Straight examining whether a psychedelic plant called ibogaine had any therapeutic benefits for people addicted to opiates.

But the 2018 story, by Travis Lupick, was differentit reflected how far psychedelic research had come in entering the mainstream.

The B.C. Centre on Substance Use, housed at the University of British Columbia, was by that time one of the world's leading centres of this field of study.

Psychedelics are not only being examined in the field of addiction medicine, but also for their efficacy in addressing posttraumatic stress disorder, depression, anxiety, and eating disorders.

Psychedelic plants and drugs have been used for thousands of years in traditional healing and spiritual ceremonies, and contemporary western science has not paid them much attention, UBC researcher Kenneth Tupper told Lupick. Now theres new interest in these traditional practices, as well as interest in bringing a clinical, scientific approach to the substances contained in these plants.

That same year,the mental-health-care company COMPASS Pathways was granted "Breakthrough Therapy" designation from the U.S. Food and Drug Administration for its psilocybin therapy for treatment-resistant depression.

This designation is granted "if preliminary clinical evidence shows that it may demonstrate substantial improvement over available therapy", according to the company, which is based in the United Kingdom.

Earlier this year, COMPASSobtained a U.S. patent for a psilocybin-therapy protocol for treating patients with depression.

Psilocybin is the ingredient that gets people high when they eat magic mushrooms.

The company stated that the psychedelic agent was "well tolerated when administered to healthy adult volunteers with support from specially trained therapists in a randomized placebo-controlled trial".

View this post on Instagram

The feds have designated it as a breakthrough therapy. From January, Compass Pathways is running a 216-patient Phase 2B clinical trialtypically the second-to-last stage before a drug gets the FDAs nodand has made enough synthetic doses of the psychoactive ingredient in magic mushrooms to supply more than 30,000 patients. Its raised $58 million in venture funding from powerful tech figures including Trump ally Peter Thiel, investor Christian Angermayer, and Bitcoin booster Michael Novogratz. Thomas Insel, former director of the U.S. National Institute of Mental Health, and Paul Summergrad, former head of the American Psychiatric Association, are on its board of advisers. The advisers bona fides are at least as important as the eight-figure funding. For the FDA to say yes to shroom therapy, youre going to have to be more rigorous, and more risk-averse, and more Catholic than the pope, says Insel, whos also an investor. Youre going to have to do this in a way that is very carefully scientific, with the best scientists, the best clinical trials, the most conservative and rigorous design, and the most careful data analysis. Read the full story by clicking the link in our bio.

A post shared by Bloomberg Businessweek (@businessweek) on Apr 5, 2020 at 6:01am PDT

There's an interesting back story to COMPASS.

It was cofounded in 2016 by the married couple George Goldsmith and Ekaterina Malievskaia when they had difficulty finding help for a family member with depression.

They obtained financial backing fromPayPal cofounder Peter Thiel and cryptocurrency kingpin Michael Novogratz, which has enabled the company to endure the long and expensive U.S regulatory process.

For more about the potential of psychedelics in treating depression, check out the video below.

Visit link:

Magic mushrooms to treat depression? COMPASS Pathways pushes forward with U.S. patent for psilocybin therapy - Straight.com

Posted in Psychedelics | Comments Off on Magic mushrooms to treat depression? COMPASS Pathways pushes forward with U.S. patent for psilocybin therapy – Straight.com